Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Anaesthesia ; 76(3): 357-365, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-32851648

RESUMO

Our study investigated whether pre-operative screening and treatment for anaemia and suboptimal iron stores in a patient blood management clinic is cost effective. We used outcome data from a retrospective cohort study comparing colorectal surgery patients admitted pre- and post-implementation of a pre-operative screening programme. We applied propensity score weighting techniques with multivariable regression models to adjust for differences in baseline characteristics between groups. Episode-level hospitalisation costs were sourced from the health service clinical costing data system; the economic evaluation was conducted from a Western Australia Health System perspective. The primary outcome measure was the incremental cost per unit of red cell transfusion avoided. We compared 441 patients screened in the pre-operative anaemia programme with 239 patients not screened; of the patients screened, 180 (40.8%) received intravenous iron for anaemia and suboptimal iron stores. The estimated mean cost of screening and treating pre-operative anaemia was AU$332 (£183; US$231; €204) per screened patient. In the propensity score weighted analysis, screened patients were transfused 52% less red cell units when compared with those not screened (rate ratio = 0.48, 95%CI 0.36-0.63, p < 0.001). The mean difference in total screening, treatment and hospitalisation cost between groups was AU$3776 lower in the group screened (£2080; US$2629; €2325) (95%CI AU$1604-5947, p < 0.001). Screening elective patients pre-operatively for anaemia and suboptimal iron stores reduced the number of red cell units transfused. It also resulted in lower total costs than not screening patients, thus demonstrating cost effectiveness.


Assuntos
Anemia/diagnóstico , Anemia/terapia , Cirurgia Colorretal/economia , Análise Custo-Benefício/métodos , Ferro/sangue , Cuidados Pré-Operatórios/métodos , Anemia/economia , Estudos de Coortes , Análise Custo-Benefício/economia , Análise Custo-Benefício/estatística & dados numéricos , Procedimentos Cirúrgicos Eletivos/economia , Transfusão de Eritrócitos/economia , Feminino , Custos de Cuidados de Saúde/estatística & dados numéricos , Humanos , Ferro/economia , Masculino , Pessoa de Meia-Idade , Cuidados Pré-Operatórios/economia , Estudos Retrospectivos , Austrália Ocidental
2.
Anaesthesia ; 74(6): 726-734, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30933308

RESUMO

Few studies have investigated if, and how, red cell transfusion and anaemia interact. We analysed 60,955 admissions to three metropolitan hospitals in Western Australia between 2008 and 2017 to determine whether the relationship between red cell transfusion and outcomes in surgical patients differed by lowest (nadir) level of haemoglobin. At levels above 100 g.l-1 , in-hospital, 30-day and 1-year mortality were higher with transfusion, the adjusted odds ratios (ORs) (95%CI) being 8.80 (4.43-17.45) p < 0.001 and 3.68 (1.93-7.02) p < 0.001 and the adjusted hazard ratio (95%CI) being 1.83 (1.28-2.61) p = 0.001, respectively. Likewise, between 90 g.l-1 and 99 g.l-1 , in-hospital, 30-day and 1-year mortality were higher with transfusion, the adjusted odds ratio (95%CI) being 3.76 (2.23-6.34) p < 0.001 and 1.96 (1.23-3.12) p < 0.001 and the adjusted hazard ratio (95%CI) being 1.34 (1.05-1.70) p = 0.017, respectively. Length of stay was longer with transfusion at nadir haemoglobin levels above 100 g.l-1 and in the following ranges: 90-99 g.l-1 , 80-89 g.l-1 , 70-79 g.l-1 and 60-69 g.l-1 , the adjusted rate ratio (95%CI) being 1.38 (1.25-1.53) p < 0.001, 1.18 (1.10-1.27) p < 0.001, 1.17 (1.13-1.22) p < 0.001, 1.07 (1.02-1.12) p = 0.003 and 1.24 (1.13-1.36) p < 0.001, respectively. Mortality was higher with red cell transfusion at haemoglobin levels greater than 90 g.l-1 , whereas at all levels below 90 g.l-1 mortality was not significantly higher or lower. Length of stay was longer with transfusion at nadir haemoglobin levels of 60 g.l-1 or above. Our results suggest that nadir haemoglobin modified the relationship between red cell transfusion and outcomes and adds to the evidence recommending caution before transfusing red cells.


Assuntos
Transfusão de Eritrócitos/mortalidade , Hemoglobinas/análise , Tempo de Internação/estatística & dados numéricos , Complicações Pós-Operatórias/mortalidade , Procedimentos Cirúrgicos Operatórios/mortalidade , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Austrália Ocidental/epidemiologia
3.
BMJ Open ; 4(10): e006337, 2014 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-25280811

RESUMO

INTRODUCTION: Coronary artery bypass grafting (CABG) and percutaneous coronary interventions (PCI) are procedures commonly performed on patients with significant obstructive coronary artery disease to relieve symptoms of ischaemia, improve survival or both. Although the efficacy of both procedures at the individual level has been established, the impact of advances in coronary artery revascularisation procedures (CARP) on long-term outcomes and cost-effectiveness at the population level are yet to be assessed. Our aim is to evaluate a minimum of 6-year outcomes and costs for the total population of patients who had CARP in Western Australia (WA) in 2000-2005. METHODS AND ANALYSIS: This retrospective population cohort study will link clinical and administrative health data for a previously defined cohort including all patients in WA who had a CARP in the period 2000-2005. The cohort consists of 19,014 patients who had 21,175 procedures (15,429 PCI and 5746 CABG). We are now collecting a minimum of 6 years follow-up of morbidity and mortality data for the cohort using the WA Data Linkage System, clinical registries and hospital records, with 12 years follow-up for cases in the year 2000. Comparison of long-term outcomes for different CARP will be reported (PCI vs CABG; bare metal stents vs drug-eluting stents vs CABG). Cost-effectiveness analysis of CARP from the perspective of the healthcare sector will be performed using individual level cost data and average costs from Australian Refined Diagnosis Related Groups. ETHICS AND DISSEMINATION: This study has received ethics approval from the University of Western Australia, the Western Australian Department of Health and all participating hospitals. Being a large population cohort study, approval included a waiver of informed consent. All findings will be presented at local, national and international healthcare/academic conferences and published in peer-reviewed journals.


Assuntos
Ponte de Artéria Coronária/métodos , Serviços de Saúde/estatística & dados numéricos , Isquemia Miocárdica/terapia , Intervenção Coronária Percutânea/métodos , Estudos de Coortes , Ponte de Artéria Coronária/economia , Análise Custo-Benefício , Coleta de Dados , Stents Farmacológicos , Seguimentos , Serviços de Saúde/economia , Humanos , Isquemia Miocárdica/economia , Avaliação de Resultados em Cuidados de Saúde , Intervenção Coronária Percutânea/economia , Estudos Retrospectivos , Stents , Austrália Ocidental
4.
Intern Med J ; 44(4): 353-61, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24528930

RESUMO

AIMS: To assess the level of evidence-based drug prescribing for acute coronary syndrome (ACS) at discharge from Western Australian (WA) hospitals and determine predictors of such prescribing in Aboriginal and non-Aboriginal patients. METHODS: All Aboriginal (2002-2004) and a random sample of non-Aboriginal (2003) hospital admissions with a principal diagnosis of ACS were extracted from the WA Hospital Morbidity Data Collection of WA Data Linkage System. Clinical information, history of co-morbidities and drugs were collected from medical notes by trained data collectors. Evidence-based prescribing (EBP) was defined as prescribing of aspirin, statin and beta-blocker or angiotensin-converting enzyme inhibitor/angiotensin II antagonist. RESULTS: Records for 1717 ACS patients discharged alive from hospitals were reviewed. The majority of patients (71%) had EBP, and there was no significant difference between Aboriginal and non-Aboriginal patients (70% vs 71%, P = 0.36). Conversely, a significantly higher proportion of Aboriginal patients had none of the drugs prescribed compared with non-Aboriginal patients (11% vs 7%, P < 0.01). EBP for ACS was independently associated with male sex (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.26-2.11), previous admission for ACS (OR 1.83, 95% CI 1.39-2.42) and diabetes (OR 1.36, 95% CI 1.04-1.79). However, ACS patients living in regional and remote areas, attending district or private hospitals, or with a history of chronic obstructive pulmonary disease were significantly less likely to have ACS drugs prescribed at discharge. CONCLUSIONS: Opportunity exists to improve prescribing of recommended drugs for ACS patients at discharge from WA hospitals in both Aboriginal and non-Aboriginal patients. Attention regarding pharmaceutical management post-ACS is particularly required for patients from rural and remote areas, and those attending district and private hospitals.


Assuntos
Síndrome Coronariana Aguda/prevenção & controle , Prescrições de Medicamentos/normas , Medicina Baseada em Evidências/métodos , Fidelidade a Diretrizes , Havaiano Nativo ou Outro Ilhéu do Pacífico , Prevenção Secundária/métodos , Síndrome Coronariana Aguda/etnologia , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Morbidade/tendências , Estudos Retrospectivos , Austrália Ocidental/epidemiologia
5.
BMJ ; 338: b36, 2009 Jan 26.
Artigo em Inglês | MEDLINE | ID: mdl-19171564

RESUMO

OBJECTIVE: To examine trends in long term survival in patients alive 28 days after myocardial infarction and the impact of evidence based medical treatments and coronary revascularisation during or near the event. DESIGN: Population based cohort with 12 year follow-up. SETTING: Perth, Australia. PARTICIPANTS: 4451 consecutive patients with a definite acute myocardial infarction according to the World Health Organization MONICA (monitoring trends and determinants in cardiovascular disease) criteria admitted to hospital during 1984-7, 1988-90, and 1991-3. MAIN OUTCOME MEASURES: All cause mortality identified from official mortality records and the hospital morbidity data, with death from cardiovascular disease as a secondary end point. RESULTS: In the 1991-3 cohort, 28 day survivors of acute myocardial infarction had a 7.6% absolute event reduction (95% confidence interval 4% to 11%) or a 28% lower relative risk reduction (16% to 38%), unadjusted for risk of death, over 12 years after the incident admission compared with the 1984-7 cohort, similar to the survival of the 1988-90 cohort. The improved survival for the 1991-3 cohort persisted after adjustment for demographic factors, coronary risk factors, severity of disease, and event complications with an adjusted relative risk reduction of 26% (14% to 37%), but this was not apparent after further adjustment for medical treatments in hospital and coronary revascularisation procedures within 12 months of the incident myocardial infarction. CONCLUSION: The improving trends in 12 year survival after a definite acute myocardial infarction are associated with progressive use of evidence based treatments during the initial admission to hospital and in the 12 months after the event. These changes in the management of acute myocardial infarction are probably contributing to the continuing decline in mortality from coronary heart disease in Australia.


Assuntos
Infarto do Miocárdio/mortalidade , Revascularização Miocárdica/mortalidade , Adulto , Estudos de Coortes , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Mortalidade/tendências , Infarto do Miocárdio/terapia , Análise de Sobrevida , Austrália Ocidental/epidemiologia
6.
Am J Epidemiol ; 168(2): 225-33, 2008 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-18468989

RESUMO

Use of troponin testing in the diagnosis of myocardial infarction substantially increases the number of cases diagnosed as myocardial infarction among suspected cases in comparison with previous criteria. However, the impact of troponin testing on rates reported in national statistics that use routinely collected hospital morbidity data is uncertain. The authors developed Poisson regression models to estimate the effect of troponin testing on long-term trends in hospital admission rates in Perth, Western Australia, from 1980 to 2004. Troponin tests were used for 10.5% of patients with suspected myocardial infarction in 1996, rising rapidly to more than 90% of patients from 2001 onward. Fitted models that assumed a continuing linear decline estimated that 100% use of troponin testing in cases of suspected myocardial infarction would lead to an apparent increase in hospital admission rates of 42% (95% confidence interval (CI): 28, 56) in men and 21% (95% CI: 4, 41) in women as compared with rates that would be expected if previous linear trends had continued. Smaller effects of 30% (95% CI: 14, 48) in men and -2% (95% CI: -21, 20) in women were found in fitted models that assumed an underlying attenuating trend in the rates. Similarly constructed logistic regression trend models found no significant effect of troponin testing on trends in 28-day case-fatality.


Assuntos
Hospitalização/estatística & dados numéricos , Infarto do Miocárdio/sangue , Troponina/sangue , Adulto , Idoso , Biomarcadores/sangue , Creatina Quinase/sangue , Creatina Quinase Forma MB/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/mortalidade , Miocárdio/patologia , Distribuição de Poisson , Análise de Regressão , Austrália Ocidental
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...